CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade XOMA Corporation - XOMA CFD

    14.06
    1.06%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.50
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    XOMA Corp ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 14.21
    Open* 14.16
    1-Year Change* -19.59%
    Day's Range* 13.88 - 14.42
    52 wk Range 13.68-26.00
    Average Volume (10 days) 18.13K
    Average Volume (3 months) 878.97K
    Market Cap 171.17M
    P/E Ratio -100.00K
    Shares Outstanding 11.47M
    Revenue 4.03M
    EPS -2.69
    Dividend (Yield %) N/A
    Beta 0.85
    Next Earnings Date Nov 1, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Sep 29, 2023 14.06 -0.10 -0.71% 14.16 14.42 13.80
    Sep 28, 2023 14.21 -0.13 -0.91% 14.34 14.66 14.16
    Sep 27, 2023 14.42 0.43 3.07% 13.99 14.61 13.77
    Sep 26, 2023 14.20 -0.09 -0.63% 14.29 14.72 13.97
    Sep 25, 2023 14.66 0.18 1.24% 14.48 14.75 14.47
    Sep 22, 2023 15.46 0.09 0.59% 15.37 15.72 15.24
    Sep 21, 2023 15.70 0.01 0.06% 15.69 16.17 15.39
    Sep 20, 2023 15.69 -0.28 -1.75% 15.97 16.19 15.34
    Sep 19, 2023 15.97 0.10 0.63% 15.87 16.42 15.87
    Sep 18, 2023 16.23 -0.76 -4.47% 16.99 17.18 16.20
    Sep 15, 2023 17.18 1.49 9.50% 15.69 17.43 15.59
    Sep 14, 2023 15.98 0.51 3.30% 15.47 16.12 15.47
    Sep 13, 2023 15.68 0.88 5.95% 14.80 15.90 14.80
    Sep 12, 2023 15.42 0.10 0.65% 15.32 15.57 14.81
    Sep 11, 2023 15.59 0.47 3.11% 15.12 15.59 14.48
    Sep 8, 2023 15.17 0.55 3.76% 14.62 15.17 14.62
    Sep 7, 2023 14.88 0.66 4.64% 14.22 15.05 14.02
    Sep 6, 2023 14.72 0.55 3.88% 14.17 14.72 13.88
    Sep 5, 2023 14.46 0.48 3.43% 13.98 14.68 13.97
    Sep 1, 2023 14.23 0.26 1.86% 13.97 14.23 13.57

    XOMA Corporation Events

    Time (UTC) Country Event
    Wednesday, November 1, 2023

    Time (UTC)

    12:30

    Country

    US

    Event

    Q3 2023 XOMA Corp Earnings Release
    Q3 2023 XOMA Corp Earnings Release

    Forecast

    -

    Previous

    -
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 XOMA Corp Earnings Release
    Q4 2023 XOMA Corp Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 6.027 38.16 29.385 18.37 5.299
    Revenue 6.027 38.16 29.385 18.37 5.299
    Total Operating Expense 23.441 20.931 16.969 22.255 22.156
    Selling/General/Admin. Expenses, Total 23.191 20.46 16.799 21.002 18.563
    Research & Development 0.153 0.171 0.17 1.253 1.682
    Unusual Expense (Income) 0 0.3 1.911
    Operating Income -17.414 17.229 12.416 -3.885 -16.857
    Interest Income (Expense), Net Non-Operating 0.255 -1.345 -0.832 -1.63 -1.465
    Other, Net 0.04 0.005 0.213 3.533 4.881
    Net Income Before Taxes -17.119 15.889 11.797 -1.982 -13.441
    Net Income After Taxes -17.104 15.798 13.298 -1.982 -13.343
    Net Income Before Extra. Items -17.104 15.798 13.298 -1.982 -13.343
    Net Income -17.104 15.798 13.298 -1.982 -13.343
    Income Available to Common Excl. Extra. Items -22.576 7.968 9.01 -1.982 -13.343
    Income Available to Common Incl. Extra. Items -22.576 7.968 9.01 -1.982 -13.343
    Diluted Net Income -22.576 7.968 9.01 -1.982 -13.343
    Diluted Weighted Average Shares 11.413 12.192 11.503 8.763 8.373
    Diluted EPS Excluding Extraordinary Items -1.9781 0.65354 0.78327 -0.22618 -1.59357
    Diluted Normalized EPS -1.9781 0.67801 0.78327 -0.22618 -1.44522
    Total Adjustments to Net Income -5.472 -7.83 -4.288 0
    Dilution Adjustment 0
    Depreciation / Amortization 0.097
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 1.658 0.437 1.486 0.451 0.983
    Revenue 1.658 0.437 1.486 0.451 0.983
    Total Operating Expense 7.615 10.607 7.696 4.823 5.75
    Selling/General/Admin. Expenses, Total 5.777 6.196 7.571 4.794 5.71
    Research & Development 0.039 0.054 0.028 0.029 0.04
    Operating Income -5.957 -10.17 -6.21 -4.372 -4.767
    Interest Income (Expense), Net Non-Operating 0.557 0.357 0.214 0.194 0.058
    Other, Net 0 0 0.005 0 0.039
    Net Income Before Taxes -5.4 -9.813 -5.991 -4.178 -4.67
    Net Income After Taxes -5.4 -9.813 -5.976 -4.178 -4.67
    Net Income Before Extra. Items -5.4 -9.813 -5.976 -4.178 -4.67
    Net Income -5.4 -9.813 -5.976 -4.178 -4.67
    Total Adjustments to Net Income -1.368 -1.368 -1.368 -1.368 -1.368
    Income Available to Common Excl. Extra. Items -6.768 -11.181 -7.344 -5.546 -6.038
    Income Available to Common Incl. Extra. Items -6.768 -11.181 -7.344 -5.546 -6.038
    Diluted Net Income -6.768 -11.181 -7.344 -5.546 -6.038
    Diluted Weighted Average Shares 11.466 11.46 11.452 11.447 11.421
    Diluted EPS Excluding Extraordinary Items -0.59027 -0.97565 -0.64129 -0.48449 -0.52868
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.4529 -0.97565 -0.64129 -0.48449 -0.52868
    Unusual Expense (Income) 1.575 0 0 0
    Depreciation / Amortization 0.224 0.225 0.097
    Other Operating Expenses, Total 0 4.132
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 61.253 96.973 88.065 59.973 47.626
    Cash and Short Term Investments 58.161 94.102 84.222 56.688 45.78
    Cash & Equivalents 56.688 45.78
    Short Term Investments 0.335 0.774
    Total Receivables, Net 2.367 0.209 1.789 2.933 1.468
    Accounts Receivable - Trade, Net 0.001 0.209 0.263 2.933 1.468
    Prepaid Expenses 0.725 0.613 0.443 0.352 0.378
    Total Assets 140.382 166.562 125.285 95.724 63.785
    Property/Plant/Equipment, Total - Net 0.036 0.213 0.38 0.544 0.059
    Property/Plant/Equipment, Total - Gross 0.129
    Accumulated Depreciation, Total -0.07
    Other Long Term Assets, Total 0.26 0.301 0.572 0.151 15.708
    Total Current Liabilities 6.818 12.967 12.302 8.875 5.703
    Accounts Payable 0.524 1.072 0.456 0.614 1.244
    Accrued Expenses 2.952 0.72 0.821 1.108 2.298
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 8.088 5.184 0.789
    Other Current Liabilities, Total 3.342 11.175 2.937 1.969 1.372
    Total Liabilities 16.368 24.686 38.861 51.736 45
    Total Long Term Debt 0 0 12.764 27.093 21.69
    Long Term Debt 0 12.764 27.093 21.69
    Other Liabilities, Total 9.55 11.719 13.795 15.768 17.607
    Total Equity 124.014 141.876 86.424 43.988 18.785
    Common Stock 0.086 0.085 0.084 0.073 0.065
    Additional Paid-In Capital 1306.27 1307.03 1267.38 1238.3 1211.12
    Retained Earnings (Accumulated Deficit) -1182.39 -1165.29 -1181.09 -1194.38 -1192.4
    Total Liabilities & Shareholders’ Equity 140.382 166.562 125.285 95.724 63.785
    Total Common Shares Outstanding 11.454 11.3153 11.2288 9.75858 8.69072
    Long Term Investments 0 1.693 0.681 0.392
    Note Receivable - Long Term 63.683 69.075 34.575 34.375
    Cash 57.826 93.328 84.222
    Other Current Assets, Total 0 2.049 1.611
    Redeemable Preferred Stock 0.049 0.049 0.049
    Total Preferred Shares Outstanding 0.9856 0.984 0.984
    Intangibles, Net 15.15
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 45.073 79.741 87.261 89.614
    Cash and Short Term Investments 44.611 78.728 83.705 88.343
    Cash 44.3 78.285 83.182 87.796
    Total Receivables, Net 0.006 0.016 2.505 0.025
    Accounts Receivable - Trade, Net 0.006 0.016 0.005 0.025
    Prepaid Expenses 0.456 0.997 1.051 0.409
    Other Current Assets, Total 0 0 0.837
    Total Assets 133.664 146.131 154.222 159.16
    Property/Plant/Equipment, Total - Net 0.073 0.081 0.126 0.17
    Long Term Investments
    Note Receivable - Long Term 73.333 66.049 66.575 69.075
    Other Long Term Assets, Total 0.26 0.26 0.26 0.301
    Total Current Liabilities 10.094 5.425 8.424 7.89
    Accounts Payable 0.437 0.985 1.153 0.787
    Accrued Expenses 6.196 1.293 1.159 1.037
    Notes Payable/Short Term Debt 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 3.461 3.147 6.112 6.066
    Total Liabilities 19.138 15.806 19.266 19.236
    Total Long Term Debt 0 0 0 0
    Long Term Debt
    Other Liabilities, Total 9.044 10.381 10.842 11.346
    Total Equity 114.526 130.325 134.956 139.924
    Redeemable Preferred Stock 0.049 0.049 0.049 0.049
    Common Stock 0.086 0.086 0.086 0.086
    Additional Paid-In Capital 1306.6 1306.61 1307.06 1307.36
    Retained Earnings (Accumulated Deficit) -1192.2 -1176.42 -1172.24 -1167.57
    Total Liabilities & Shareholders’ Equity 133.664 146.131 154.222 159.16
    Total Common Shares Outstanding 11.461 11.4508 11.4238 11.4099
    Total Preferred Shares Outstanding 0.9856 0.984 0.984 0.984
    Short Term Investments 0.311 0.443 0.523 0.547
    Intangibles, Net 14.925
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -17.104 15.798 13.298 -1.982 -13.343
    Cash From Operating Activities -12.879 22.678 10.092 -0.285 -12.644
    Cash From Operating Activities 0.007 0.007 0.022 0.025 0.03
    Non-Cash Items 4.302 7.759 -3.415 5.767 3.651
    Cash Interest Paid 0 0.311 0.692 0.558 0.081
    Changes in Working Capital -0.181 -0.886 0.187 -4.095 -2.982
    Cash From Investing Activities -20.221 -26.5 -0.209 -19.3 -15.006
    Capital Expenditures -15.247 0 -0.009 0 -0.006
    Other Investing Cash Flow Items, Total -4.974 -26.5 -0.2 -19.3 -15
    Cash From Financing Activities -4.451 12.835 19.793 30.493 29.939
    Issuance (Retirement) of Stock, Net 2.419 41.584 29.45 22.539 22.915
    Issuance (Retirement) of Debt, Net 0 -21.377 -5.33 8.547 7.487
    Foreign Exchange Effects 0 0.02
    Net Change in Cash -37.551 9.013 29.676 10.908 2.309
    Financing Cash Flow Items -1.398 -3.873 -4.327 -0.593 -0.463
    Cash Taxes Paid 0.076 0 1.637
    Total Cash Dividends Paid -5.472 -3.499
    Amortization 0.097
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -9.813 -17.104 -11.128 -6.95 -2.28
    Cash From Operating Activities -4.924 -12.879 -8.989 -5.326 -1.009
    Cash From Operating Activities 0.001 0.007 0.007 0.003 0.002
    Non-Cash Items 1.764 4.302 3.162 2.235 1.332
    Cash Interest Paid 0 0 0 0 0.095
    Changes in Working Capital 2.899 -0.181 -1.03 -0.614 -0.063
    Cash From Investing Activities -7.234 -20.221 -4.974 -5 -5
    Other Investing Cash Flow Items, Total -7.234 -4.974 -4.974 -5 -5
    Cash From Financing Activities -1.368 -4.451 -3.129 -1.869 -0.735
    Financing Cash Flow Items 0 -1.398 -1.398 -1.038 -0.973
    Issuance (Retirement) of Stock, Net 0 2.419 2.373 1.905 1.606
    Issuance (Retirement) of Debt, Net 0 0 0 0
    Net Change in Cash -13.526 -37.551 -17.092 -12.195 -6.744
    Total Cash Dividends Paid -1.368 -5.472 -4.104 -2.736 -1.368
    Capital Expenditures -15.247
    Cash Taxes Paid 0.076 0.095 0.095
    Amortization 0.225 0.097

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    XOMA Corporation Company profile

    About XOMA Corp

    XOMA Corporation (XOMA) is a biotechnology royalty aggregator. The Company's drug royalty aggregator business is focused on early to mid-stage clinical assets primarily in Phase I and II. XOMA acquires pre-commercial therapeutic candidates that are licensed to pharmaceutical or biotechnology companies. The Company's portfolio of partner-funded programs spans multiple stages of the drug development process and across various therapeutic areas. The Company's royalty-aggregator business includes acquiring additional licenses to programs with third-party funding and has more than 70 assets. XOMA royalty portfolio includes NIS793, anti-transforming growth factor-beta (TGFb) antibody program; gevokizumab (VPM087); mezagitamab (TAK-079), iscalimab (CFZ533), and MK-4830.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, XOMA Corp revenues increased 30% to $38.2M. Net income applicable to common stockholders decreased 12% to $8M. Revenues reflect Europe segment increase of 40% to $35M, United States segment increase from $1.3M to $2.6M. Net income was offset by Stock-based Compensation in SGA increase of 56% to $6.2M (expense).

    Equity composition

    Common Stock $.0075 Par, 03/11, 46,666,666 auth., 29,510,963 issd. Insiders own 7.83%. PO: 4/91, 3.4M shs @ $26.50 by Alex. Brown& Sons. PO 6/01, 3M shs @ $15 by U.S. Bancorp Piper Jaffray. Series B Prfd. Stock $.05 Par, 8K auth., 2,959 issd. *1996, Co.'s 4% Conv. Subd. Debentures were conv. into 2M shs. of Common. 08/10, 1-for-15 reverse split.

    Industry: Bio Therapeutic Drugs

    Suite 310
    2200 Powell Street
    EMERYVILLE
    CALIFORNIA 94608
    US

    Income Statement

    • Annual
    • Quarterly

    News

    How to Trade The Triple Top

    Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

    14:13, 27 September 2023
    USA flag on the background of stock charts. Financial system in USA

    Q4 lookahead: US indices starting to show signs of trouble?

    US indices start to draw attention as traders focus on the outlook for Q4.

    07:20, 27 September 2023

    USD/JPY Climbs Towards Key Highs

    USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

    11:32, 26 September 2023

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    People also watch

    ETH/USD

    1,678.32 Price
    -0.300% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    XRP/USD

    0.52 Price
    +0.020% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    Oil - Crude

    90.04 Price
    -1.230% 1D Chg, %
    Long position overnight fee 0.0661%
    Short position overnight fee -0.0881%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    US100

    14,744.20 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0039%
    Overnight fee time 21:00 (UTC)
    Spread 7.0

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading